Subscribe To

Price Alert Latest News Economic Calendar News

MRNA / UBS upgrades Moderna to buy while cutting price target

UBS upgraded its rating on vaccine maker Moderna MRNA, -1.64% to buy from neutral on valuation grounds, but cut its price target to $191 from $221. “We acknowledge the uncertainty around the commercial/endemic COVID market and uncertainty around '23 revenues, which has been a key investor focus and headwind,” said analysts led by Eliana Merle. Read More

Demo Live Account See Partner Details

Content Topics

Upgrades

Moderna

While

Cutting

Price

Target

Stock

MRNA

Posted: Jun 26 2023, 06:06

Author Name: Market Watch

MRNA News

By The Motley Fool
November 4, 2023

Moderna May Be Facing Its Toughest Moment Ever. Time to Sell?

Moderna reported a billion-dollar loss in the third quarter and began downsizing its manufacturing infrastructure to match lower levels of vaccine dem

By Zacks Investment Research
November 3, 2023

Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2023, it might be worth cons

By Yahoo Finance
November 2, 2023

Moderna CEO discusses earnings and how the company aims to break even by 2026

While boasting a third-quarter revenue beat, biotech firm Moderna (MRNA) reported an overwhelmingly higher-than-expected loss of $9.53 per share. Its

By Investopedia
November 2, 2023

Moderna Shares Slide After Posting a Loss on Falling COVID-19 Vaccine Sales and Production

Moderna (MRNA) shares tumbled over 6% Thursday after reporting a steep loss as the drug maker lost sales and cut back on making its COVID-19 vaccine,

By Seeking Alpha
November 2, 2023

Moderna, Inc. (MRNA) Q3 2023 Earnings Call Transcript

Moderna, Inc. (NASDAQ:MRNA ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of Investor Rela

By Proactive Investors
November 2, 2023

Moderna stock plummets on 3Q loss and weak sales guidance

Moderna Therapeutics Inc (NASDAQ:MRNA) stock moved lower on Thursday after the drugmaker's weak full-year sales forecast and a significant loss for th

By CNBC Television
November 2, 2023

Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots

CNBC's Becky Quick reports on the company's quarterly earnings results.

By Reuters
November 2, 2023

Moderna revenue tops expectations, expects to return to sales growth in 2025

Moderna on Thursday said it expected 2023 revenue of at least $6 billion, a decline reflecting weaker demand for COVID-19 vaccines this year, but that

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.